n-hydroxysuccinimide has been researched along with B16 Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, A; Chou, SH; Geng, Y; Morris, T; Munirathinam, G; Pipathsouk, A; Shetty, AV; Tan, I; Wang, B; Xu, L; Zheng, G | 1 |
1 other study(ies) available for n-hydroxysuccinimide and B16 Melanoma
| Article | Year |
|---|---|
Palmitate-derivatized human IL-2: a potential anticancer immunotherapeutic of low systemic toxicity.
Topics: Animals; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Melanoma, Experimental; Mice; Mice, Transgenic; Palmitic Acid; Recombinant Proteins; Succinimides; T-Lymphocytes, Cytotoxic | 2013 |